S-1: INVO Fertility Registers 8.3M Shares for Resale

INVO Fertility, Inc. filed an S-1 registration statement for the resale of up to 8,345,774 shares of common stock by Five Narrow Lane LP, with no direct proceeds to the company from the sale.

Summary

• INVO Fertility, Inc. (IVF) filed an S-1 registration statement for the resale of up to 8,345,774 shares of common stock by Five Narrow Lane LP (FNL).
• The registered shares include 770,973 shares issuable upon exercise of an Inducement Warrant and 7,574,801 shares issuable upon conversion of Series C-2 Non-Voting Convertible Preferred Stock.
• The company will not receive any proceeds from FNL's sale of these shares, but may receive up to $344,000 upon FNL's exercise of the Inducement Warrant.
• INVO Fertility is a healthcare services and technology company focused on expanding access to assisted reproductive technology (ART) care.
• The company's strategy involves building, acquiring, and operating fertility clinics, including INVO Centers (offering the INVOcell IVC procedure) and profitable in vitro fertilization (IVF) clinics.
• Currently, the company operates two INVO Centers and one IVF clinic in the United States.
• The acquisition of Wisconsin Fertility Institute (WFI) on August 10, 2023, more than tripled annual revenue and became a significant source of positive cash flow.
• INVOcell is a proprietary medical device for intravaginal culture (IVC), offering a lower-cost alternative to traditional IVF with comparable success rates.
• The company divested an 80.1% ownership interest in NAYA Therapeutics, Inc. in May 2025 to refocus exclusively on the fertility marketplace.
• FNL holds an 'Additional Investment Right' to purchase up to $10 million of additional Series C-2 Preferred shares, with a minimum exercise amount of $200,000.
• The conversion price for Series C-2 Preferred and AIR Preferred Shares is subject to adjustment, potentially reducing to the lowest of the current conversion price or the greater of a Floor Price ($0.612 per share) and 85% of the average of the three lowest VWAPs during the ten trading days prior to exercise.
• The Second Amended and Restated Debenture has been paid in full and fully extinguished as of September 29, 2025.
• The company's common stock is listed on the Nasdaq Capital Market under the symbol IVF, with a last reported sale price of $0.7283 per share on October 13, 2025.
• The total outstanding common stock after this offering is expected to be 13,969,786 shares, based on 5,624,012 shares outstanding as of October 13, 2025.

Sentiment

Score: 5

Explanation: The filing is primarily a technical registration for resale, not a performance update. While it highlights strategic growth (clinic acquisitions, INVOcell) and potential future capital raises, it also emphasizes significant dilution risks and the speculative nature of the investment. The auditor's going concern warning (mentioned in the incorporated audit report) is a notable negative, balancing the positive strategic developments.

Positives

• The acquisition of Wisconsin Fertility Institute (WFI) more than tripled annual revenue and became a significant source of positive cash flow.
• The company has refocused exclusively on the fertility marketplace after divesting most of NAYA Therapeutics, Inc.
• INVOcell technology offers a more affordable and intimate ART option with comparable success rates to traditional IVF.
• Dedicated INVO Centers require less investment and are operationally efficient, making them ideal for underserved secondary markets.
• The company has the potential to receive up to $344,000 from FNL's exercise of the Inducement Warrant.
• FNL has an Additional Investment Right to purchase up to $10 million in Series C-2 Preferred, providing a potential source of future capital.

Negatives

• The company will not receive any proceeds from the sale of shares by the Selling Stockholder (FNL), except for potential warrant exercise proceeds.
• Investing in the company's securities is highly speculative and involves a high degree of risk.
• Sales by the Selling Stockholder below current market prices could adversely affect the market price of the common stock.
• The issuance of common stock upon conversion of Series C-2 Preferred or exercise of warrants may cause substantial dilution to existing stockholders.
• The sale of a substantial number of shares by FNL could cause the trading price to decline or make future equity raises more difficult.
• The conversion price of Series C-2 Preferred and AIR Preferred Shares is subject to reduction, potentially leading to greater dilution for investors.
• Management has broad discretion over the use of proceeds from AIR Preferred Shares, which may not always improve operating results or enhance stock value.

Risks

• An investment in the company's securities is highly speculative and involves a high degree of risk.
• The Selling Stockholder may choose to sell the shares at prices below the current market price, which could adversely affect the market price of the common stock.
• Media coverage regarding the company may be inaccurate, misleading, or omit information not directly attributable to management.
• It is not possible to predict the actual number of Series C-2 Preferred shares that will be sold under the Additional Investment Right or the actual gross proceeds, which may impact future liquidity.
• Investors who buy shares at different times may pay different prices and experience different levels of dilution and investment outcomes.
• The conversion price per share of the Series C-2 Preferred is subject to reduction, potentially causing a decline in the value of shares purchased by investors.
• The issuance of common stock to FNL upon conversion of Series C-2 Preferred or exercise of Inducement Warrants may cause substantial dilution to existing stockholders.
• The sale of a substantial number of shares by FNL could cause the trading price of common stock to decline or make it more difficult for the company to sell equity in the future.
• Management will have broad discretion over the use of net proceeds from the sale of AIR Preferred Shares, and these proceeds may not be invested successfully or improve operating results.
• Investments of net proceeds in short-term, investment-grade instruments may not yield a favorable return to stockholders.
• The company's ability to continue as a going concern, as noted in the auditor's report incorporated by reference, poses a significant risk.

Future Outlook

The company plans to continue its strategy of acquiring profitable IVF clinics and opening additional wholly-owned INVO Centers in the coming years. It also intends to seek out additional, innovative fertility-focused technologies to license or acquire to utilize within its clinics. Management will have broad discretion over the use of proceeds from the Additional Investment Right, primarily for acquisitions of additional fertility clinics and related businesses, capital expenditures, working capital, and general and administrative expenses.

Industry Context

The company operates in the fertility marketplace, focusing on expanding access to assisted reproductive technology (ART) care. It positions its INVOcell technology and INVO Centers as more affordable and efficient alternatives to traditional IVF, potentially serving underserved secondary markets. The strategy of acquiring profitable IVF clinics complements its INVO Center expansion, indicating a hybrid approach to market penetration and growth within the fertility sector.

Comparison to Industry Standards

• The INVOcell IVC procedure can deliver comparable pregnancy success and live birth rates to traditional IVF at a lower cost.
• The INVOcell IVC procedure is significantly more effective as a treatment than intrauterine insemination (IUI).
• Dedicated INVO Centers require less investment than traditional IVF clinics and are operationally efficient.

Corporate Governance

Legal Proceedings

• A Settlement and Mutual Release Agreement was executed on September 30, 2025, by and among Dr. Elizabeth Pritts, Fertility Labs of Wisconsin, LLC, Wood Violet Fertility LLC, Wisconsin Fertility and Reproductive Surgery Associates, S.C., INVO Centers, LLC, and INVO Fertility, Inc.

Related Party Transactions

• Five Narrow Lane LP (FNL) is the Selling Stockholder and has an 'Additional Investment Right' to purchase up to $10 million of aggregate stated value of additional Series C-2 Preferred shares.
• FNL was a party to several agreements with the company, including the Inducement Letter Agreement (April 30, 2025), May 2025 FNL Amendment and Exchange Agreement, AIR Exercise and Reload Agreement (June 29, 2025), August 2025 FNL Amendment and Exchange Agreement (August 21, 2025), and September 2025 FNL Exchange Agreement (September 29, 2025).
• Joseph Hammer and Arie Rabinowitz are identified as the natural control persons of Five Narrow Lane LP, having voting and disposition control over the shares.

Stakeholder Impact

• Shareholders face significant potential dilution from the conversion of Series C-2 Preferred and exercise of warrants by FNL, which could negatively impact the market price of common stock.
• New investors are exposed to a high degree of risk and speculative investment, with potential for varying prices and dilution levels.
• The company will not receive direct proceeds from FNL's share sales, but stands to gain up to $344,000 from warrant exercise and potentially up to $10 million in capital from FNL's Additional Investment Right, which can fund strategic growth initiatives.
• The company's strategic focus on expanding fertility clinics and technology could benefit patients by increasing access to ART care.

Next Steps

• Five Narrow Lane LP (FNL) may sell or otherwise dispose of the registered shares.
• The company plans to open additional wholly-owned INVO Centers in the coming years.
• The company intends to seek out additional, innovative fertility-focused technologies to license or acquire.
• Management will use net proceeds from AIR Preferred Shares primarily for acquisitions of additional fertility clinics and related businesses, capital expenditures, working capital, and general and administrative expenses.

Key Dates

Recommendation

The filing indicates substantial risks, primarily the significant potential for dilution from the conversion of Series C-2 Preferred and warrants, which could exert downward pressure on the stock price. The adjustable conversion price mechanism further exacerbates dilution risk for existing shareholders. While the company outlines a growth strategy and potential for future capital raises, the immediate impact of a large volume of shares being registered for resale by a single institutional investor, coupled with the auditor's going concern warning (from incorporated documents), suggests a negative outlook for the stock price in the short to medium term. A seasoned investor would likely view this as a signal to reduce exposure due to impending dilution and market overhang.

Keywords

INVO Fertility, IVF, INVOcell, fertility treatment, assisted reproductive technology, ART, S-1 filing, common stock, preferred stock, warrants, dilution, Nasdaq, healthcare services, medical device, equity offering, Five Narrow Lane LP, SEC filing